Founded in August 1990 and registered in California, Schrodinger, Inc. has developed a physics-based computational platform that accurately predicts key molecular properties, enabling faster and more cost-effective discovery of high-quality, novel molecules for drug development and material applications. Their software is utilized by biopharmaceutical companies, industrial firms, academic institutions, and government laboratories around the globe. As a leading provider of computational software solutions for drug discovery, the company offers a range of software solutions that accelerate various stages of molecular discovery, design, and optimization. Additionally, they leverage their platform and expertise through a series of collaborative and wholly-owned drug discovery programs that target a wide array of disease indications.